5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.53▼ | 4.53▼ | 4.53▼ | 4.45▼ | 4.62▼ |
MA10 | 4.48▲ | 4.47▲ | 4.47▲ | 4.54▼ | 4.72▼ |
MA20 | 4.51▼ | 4.56▼ | 4.57▼ | 4.66▼ | 5.30▼ |
MA50 | 4.61▼ | 4.64▼ | 4.74▼ | 4.76▼ | 10.52▼ |
MA100 | 4.76▼ | 4.72▼ | 4.71▼ | 5.37▼ | 56.91▼ |
MA200 | 4.81▼ | 4.72▼ | 4.73▼ | 8.40▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.020▲ | 0.015▲ | 0.014▲ | -0.023▼ | 0.614▲ |
RSI | 47.235▼ | 46.990▼ | 46.712▼ | 44.803▼ | 30.973▼ |
STOCH | 89.074▲ | 88.024▲ | 82.251▲ | 25.337 | 28.480 |
WILL %R | -31.034 | -28.125 | -47.727 | -89.444▼ | -76.035▼ |
CCI | 55.375 | 45.528 | 23.831 | -79.996 | -108.635▼ |
Wednesday, April 24, 2024 10:22 AM
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders ...
|
Wednesday, April 24, 2024 06:15 AM
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received ...
|
Tuesday, April 23, 2024 09:00 AM
Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/04/24 | 4.45 | 4.60 | 4.413 | 4.413 | 3,503 |
24/04/24 | 4.58 | 4.6899 | 4.4807 | 4.56 | 14,442 |
23/04/24 | 4.39 | 4.79 | 4.3813 | 4.57 | 40,601 |
22/04/24 | 4.50 | 4.50 | 4.2001 | 4.36 | 53,626 |
19/04/24 | 4.64 | 4.71 | 4.252 | 4.33 | 29,905 |
18/04/24 | 4.73 | 4.95 | 4.60 | 4.66 | 42,233 |
17/04/24 | 4.69 | 4.9586 | 4.375 | 4.80 | 121,996 |
16/04/24 | 4.50 | 4.89 | 4.43 | 4.6501 | 93,298 |
15/04/24 | 4.72 | 4.80 | 4.42 | 4.42 | 95,422 |
12/04/24 | 4.83 | 5.0374 | 4.57 | 4.6865 | 82,800 |
|
|
||||
|
|
||||
|
|